Recent studies have shown that mCRC patients with MSI‐H tumors respond to immunotherapy given mainly as third‐line treatment.18, 19, 20 The recently updated National Comprehensive Cancer Network guidelines recommend second‐line treatment with a PD‐1 inhibitor in patients with MSI‐H tumor and addition of BRAF‐inhibitors to standard treatment in patients with mutBRAF tumors.21 For these reasons, it is important to know the proper frequency, clinical characteristics, prognosis and treatment response in patients with MSI‐H and mutBRAF tumors in population‐based cohorts. Here, BRAF is linked to neoplasm.